A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors

Trial Profile

A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Olaratumab (Primary) ; Doxorubicin; Ifosfamide; Irinotecan; Vincristine
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 30 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 15 Jul 2016 Planned initiation date changed from 1 Jun 2016 to 1 Aug 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top